Osteoporosis diagnosis and screening

Clinical Cornerstone

Volumn 8, Issue 1, 2006, Pages 9-18

  Singer, Andrea ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE DENSITY; BONE MASS; DIAGNOSTIC ACCURACY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PATIENT IDENTIFICATION; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; UNITED STATES; VERTEBRA FRACTURE; WORLD HEALTH ORGANIZATION;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34250684159     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(06)80061-X     Document Type: Article

References (29)

1. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation (2002), National Osteoporosis Foundation, Washington, DC
2. Available at. National Osteoporosis Foundation. Fast facts. Accessed August 15 (2006). http://www.nof.org/osteoporosis/diseasefacts.htm
3. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85 (2000) 4118-4124
4. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
5. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 (2000) 604-610
6. Ringe J.D., Faber H., and Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 86 (2001) 5252-5255
7. Sorensen O.H., Crawford G.M., Mulder H., et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
8. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
9. Ringe J.D., Faber H., Farahmand P., and Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. Rheumatol Int 26 (2006) 427-431
10. Available at:. World Health Organization. Prevention and management of osteoporosis. Accessed August 27. WHO Technical Report series 921 (2006). http://whglibdoc.who.int/trs/WHO_TRS_921.pdf
11. van der Klift M., de Laet C.D., and Pols H.A. Assessment of fracture risk: Who should be treated for osteoporosis?. Best Pract Res Clin Rheumatol 19 (2005) 937-950
12. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis (2003), National Osteoporosis Foundation, Washington, DC
13. Lewiecki E.M., Watts N.B., McClung M.R., et al. Position statement. Official positions of the International Society for Clinical Densitomerry. J Clin Endocrinol Metab 89 (2004) 3651-3655
14. Lane N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194 (2006) S3-S11
15. Siris E.S., Chen Y.T., Abbott T.A., et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164 (2004) 1108-1112
16. Gudmundsdottir S.L., Indridason O.S., Franzson L., and Sigurdsson G. Age-related decline in bone mass measured by dual-energy X-ray absorptiometry and quantitative ultrasound in a population-based sample of both sexes: Identification of useful ultrasound thresholds for osteoporosis screening. J Clin Densitom 8 (2005) 80-86
17. Picard D., Brown J.P., Rosenthall L., et al. Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement. J Clin Densitom 7 (2004) 111-118
18. Moayyeri A., Soltani A., Bahrami H., et al. Preferred skeletal site for osteoporosis screening in high-risk populations. Public Health 120 (2006) 863-871
19. ACOG Committee Opinion. Bone density screening for osteoporosis. Int J Gynaecol Obstet 77 (2002) 299-301
20. Edwards B.J., Brooks E.R., and Langman C.B. Osteoporosis screening of postmenopausal women in the primary care setting: A case-based approach. Gender Med 1 (2004) 70-85
21. Nishihara S., Fujita H., Iida T., et al. Evaluation of osteoporosis in X-ray CT examination: A preliminary study for an automatic recognition algorithm for the central part of a vertebral body using abdominal X-ray CT images. Comput Med Imaging Graph 29 (2005) 259-266
22. Briot K., and Roux C. What is the role of DXA, QUS, and bone markers in fracture prediction, treatment allocation and monitoring?. Best Pract Res Clin Rheumatol 19 (2005) 951-964
23. Nayak S., Olkin I., Liu H., et al. Meta-analysis: Accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med 144 (2006) 832-841
24. The Writing Group for the ISCD Position Development Conference. Position statement: Executive summary. J Clin Densitom 7 (2004) 7-12
25. Cadarette S.M., Jaglal S.B., Kreiger N., et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ 162 (2000) 1289-1294
26. Weinstein L., and Ullery B. Identification of at-risk women for osteoporosis screening. Am J Obstet Gynecol 183 (2000) 547-549
27. Cadarette S.M., Jaglal S.B., and Murray T.M. Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry. Osteoporos Int 10 (1999) 85-90
28. Cadarette S.M., Jaglal S.B., Murray T.M., et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 286 (2001) 57-63
29. Richy F., Gourlay M., Ross P.D., et al. Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. QJM 97 (2004) 39-46